<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02344628</url>
  </required_header>
  <id_info>
    <org_study_id>LSHTM-8832</org_study_id>
    <nct_id>NCT02344628</nct_id>
  </id_info>
  <brief_title>Comparison of Two Different Doses of Azithromycin for Treatment of Yaws</brief_title>
  <official_title>Randomized Controlled Trial Comparing Efficacy of Single Dose Treatment of Yaws With 20mg/kg Versus 30mg/kg of Azithromycin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>London School of Hygiene and Tropical Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>World Health Organization</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centers for Disease Control and Prevention</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kwame Nkrumah University of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Barcelona Institute for Global Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Papua New Guinea Institute of Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ghana Health Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Noguchi Memorial Institute for Medical Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Papua New Guinea National Department of Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Health and Allied Sciences, Ho, Volta Region, Ghana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>London School of Hygiene and Tropical Medicine</source>
  <brief_summary>
    <textblock>
      The study will be a single blinded, randomized, controlled open label non-inferiority phase
      III, trial with two parallel groups, conducted in Ghana and Papua New Guinea (PNG). The
      ultimate goal is to establish if a 20mg/kg dose of azithromycin is as effective as a 30mg/kg
      dose in the treatment of yaws. Approximately 600 clinically and serologically diagnosed yaws
      patients will be included in the study. Patients will be randomized to receive treatment with
      the two antibiotic regimens as follow: (i) Regimen I (AZT20): Single oral dose of 20 mg/kg
      azithromycin (ii) Regimen II (AZT30): Single oral dose of 30 mg/kg azithromycin. The
      follow-up period of patients will be 6 months. Assessments before, during and after the
      antibiotic treatment will include full medical history, clinical assessment of the lesion
      and, laboratory investigations. The primary efficacy parameters are healing of the lesion at
      4 weeks and a four-fold decline in RPR titre at 6 months after start of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Clinical and Serological Cure</measure>
    <time_frame>6 Months</time_frame>
    <description>Clinical resolution of skin lesion at 4 weeks and at least four-fold decline in Rapid Plasma Reagin titre or seroreversion at 6-month (compared to baseline) in T.pallidum subsp. pertenue Polymerase Chain Reaction-confirmed subjects with yaws.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Clinical and Serological Cure in Latent Yaws</measure>
    <time_frame>6 Months</time_frame>
    <description>Clinical resolution of skin lesion at 4 weeks and at least four-fold decline in Rapid Plasma Reagin titre or seroreversion at 6-month (compared to baseline) in T.pallidum subsp. pertenue Polymerase Chain Reaction-negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>6 months</time_frame>
    <description>To compare the incidences and relative risk of all Adverse Events (AEs), including treatment-related AEs, Serious Adverse Events (SAEs) and grade 3-4 toxicity in patients treated with AZT20 and AZT30 regimens</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">583</enrollment>
  <condition>Yaws</condition>
  <arm_group>
    <arm_group_label>AZT30</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AZT20</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Comparison of two different dosing strategies for the treatment of yaws</description>
    <arm_group_label>AZT20</arm_group_label>
    <arm_group_label>AZT30</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged 6 to 16 years

          -  Clinical lesion consistent with primary or secondary yaws -Primary ulcer or papilloma

          -  Dually-Positive Chembio DPP Syphilis Screen &amp; Confirm

          -  Informed Consent and Assent (for children 12-16 years)

        Exclusion Criteria:

          1. Known allergy to azithromycin or macrolides.

          2. Treatment with long-acting penicillin or alternative antibiotic with activity against
             T. pallidum within the last 3 months (ceftriaxone, azithromycin or doxycycline,
             amoxicillin).

          3. Patients with current treatment with any drugs likely to interact with the study
             medication.

          4. Patients who are unable to take oral medication or having gastrointestinal disease
             likely to interfere with drug absorption.

          5. Patients who may not be able to comply with the requirements of the study protocol
             including follow up visits.

          6. Patients who are not willing to give informed consent (patient and/or parent/legal
             representative), or who withdraw consent.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Mabey</last_name>
    <role>Principal Investigator</role>
    <affiliation>London School of Hygiene and Tropical Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>School Based Recruitment</name>
      <address>
        <city>Ayensuanor District</city>
        <state>Eastern Region</state>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School Based Recruitment</name>
      <address>
        <city>Upper West Akyem</city>
        <state>Eastern Region</state>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School Based Recruitment</name>
      <address>
        <city>West Akyem District</city>
        <state>Eastern Region</state>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>School Based Recruitment</name>
      <address>
        <city>Nkwanta North District</city>
        <state>Volta Region</state>
        <country>Ghana</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Based Recruitment</name>
      <address>
        <city>Karkar District</city>
        <state>Madang Province</state>
        <country>Papua New Guinea</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Based Recruitment</name>
      <address>
        <city>Kavieng Subdistrict</city>
        <state>New Ireland Province</state>
        <country>Papua New Guinea</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London School of Hygiene and Tropical Medicine</name>
      <address>
        <city>London</city>
        <zip>WC1E 7HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Ghana</country>
    <country>Papua New Guinea</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <study_first_submitted>January 17, 2015</study_first_submitted>
  <study_first_submitted_qc>January 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 26, 2015</study_first_posted>
  <results_first_submitted>January 19, 2018</results_first_submitted>
  <results_first_submitted_qc>February 19, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 3, 2018</results_first_posted>
  <last_update_submitted>October 2, 2018</last_update_submitted>
  <last_update_submitted_qc>October 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 31, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Yaws</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AZT30</title>
          <description>Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams
Azithromycin: Comparison of two different dosing strategies for the treatment of yaws</description>
        </group>
        <group group_id="P2">
          <title>AZT20</title>
          <description>Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams
Azithromycin: Comparison of two different dosing strategies for the treatment of yaws</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="291"/>
                <participants group_id="P2" count="292"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="200">4/52 clinical data was available for 283. Serological data 6/12 for 212. Both were available for 200</participants>
                <participants group_id="P2" count="206">4/52 clinical data was available for 286. Serological data 6/12 for 218. Both were available for 206</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
                <participants group_id="P2" count="86"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZT30</title>
          <description>Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams
Azithromycin: Comparison of two different dosing strategies for the treatment of yaws</description>
        </group>
        <group group_id="B2">
          <title>AZT20</title>
          <description>Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams
Azithromycin: Comparison of two different dosing strategies for the treatment of yaws</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="291"/>
            <count group_id="B2" value="292"/>
            <count group_id="B3" value="583"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="B2" value="10" lower_limit="8" upper_limit="12"/>
                    <measurement group_id="B3" value="10" lower_limit="8" upper_limit="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="88"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="208"/>
                    <measurement group_id="B2" value="204"/>
                    <measurement group_id="B3" value="412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Papua New Guinea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="92"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ghana</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Clinical and Serological Cure</title>
        <description>Clinical resolution of skin lesion at 4 weeks and at least four-fold decline in Rapid Plasma Reagin titre or seroreversion at 6-month (compared to baseline) in T.pallidum subsp. pertenue Polymerase Chain Reaction-confirmed subjects with yaws.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZT30</title>
            <description>Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams
Azithromycin: Comparison of two different dosing strategies for the treatment of yaws</description>
          </group>
          <group group_id="O2">
            <title>AZT20</title>
            <description>Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams
Azithromycin: Comparison of two different dosing strategies for the treatment of yaws</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical and Serological Cure</title>
          <description>Clinical resolution of skin lesion at 4 weeks and at least four-fold decline in Rapid Plasma Reagin titre or seroreversion at 6-month (compared to baseline) in T.pallidum subsp. pertenue Polymerase Chain Reaction-confirmed subjects with yaws.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="76"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Clinical and Serological Cure in Latent Yaws</title>
        <description>Clinical resolution of skin lesion at 4 weeks and at least four-fold decline in Rapid Plasma Reagin titre or seroreversion at 6-month (compared to baseline) in T.pallidum subsp. pertenue Polymerase Chain Reaction-negative.</description>
        <time_frame>6 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZT30</title>
            <description>Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams
Azithromycin: Comparison of two different dosing strategies for the treatment of yaws</description>
          </group>
          <group group_id="O2">
            <title>AZT20</title>
            <description>Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams
Azithromycin: Comparison of two different dosing strategies for the treatment of yaws</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Clinical and Serological Cure in Latent Yaws</title>
          <description>Clinical resolution of skin lesion at 4 weeks and at least four-fold decline in Rapid Plasma Reagin titre or seroreversion at 6-month (compared to baseline) in T.pallidum subsp. pertenue Polymerase Chain Reaction-negative.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="124"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>To compare the incidences and relative risk of all Adverse Events (AEs), including treatment-related AEs, Serious Adverse Events (SAEs) and grade 3-4 toxicity in patients treated with AZT20 and AZT30 regimens</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZT30</title>
            <description>Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams
Azithromycin: Comparison of two different dosing strategies for the treatment of yaws</description>
          </group>
          <group group_id="O2">
            <title>AZT20</title>
            <description>Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams
Azithromycin: Comparison of two different dosing strategies for the treatment of yaws</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>To compare the incidences and relative risk of all Adverse Events (AEs), including treatment-related AEs, Serious Adverse Events (SAEs) and grade 3-4 toxicity in patients treated with AZT20 and AZT30 regimens</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="291"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZT30</title>
          <description>Single dose of azithromycin at a dose of 30mg/kg - max 2 Grams
Azithromycin: Comparison of two different dosing strategies for the treatment of yaws</description>
        </group>
        <group group_id="E2">
          <title>AZT20</title>
          <description>Single dose of azithromycin at a dose of 20mg/kg - max 1 Grams
Azithromycin: Comparison of two different dosing strategies for the treatment of yaws</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Itching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="292"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="291"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="292"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Michael Marks</name_or_title>
      <organization>London School of Hygiene and Tropical Medicine</organization>
      <phone>+447984643424</phone>
      <email>michael.marks@lshtm.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

